A Phase II Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic Melanoma
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2018
At a glance
- Drugs Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 02 Oct 2018 Status changed from suspended to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 15 Aug 2018 Status changed from recruiting to suspended as amendment 3 pending IRB approval.